Related Experiment Video

Updated: Mar 19, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

Prospects and advances of PROTAC in the treatment of hematologic malignancies

Xinyang Wang1,2,3, Ming Zhang1,2,3, Heng Mei4,5,6

  • 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.

Experimental Hematology & Oncology
|March 18, 2026
PubMed

Insights

Targeted protein degradation using Proteolysis-Targeting Chimeras (PROTACs) offers a novel therapeutic strategy for hematologic malignancies. This review highlights PROTACs in clinical trials and preclinical development for these cancers.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Targeted protein degradation (TPD) is a rapidly advancing field for treating hematologic malignancies.
  • Proteolysis-Targeting Chimeras (PROTACs) leverage the ubiquitin-proteasome system to degrade target proteins.
  • PROTACs present advantages over small-molecule inhibitors and CAR-T therapies in mechanism, toxicity, specificity, and resistance.

Purpose of the Study:

  • To review PROTAC drugs in clinical trials for hematologic malignancies.
  • To classify preclinical protein targets for PROTAC development.
  • To provide an overview of the current PROTAC landscape and future directions in hematologic malignancies.

Main Methods:

  • Comprehensive literature review of PROTACs in clinical trials.
  • Classification of 56 preclinical protein targets based on function.
  • Analysis of PROTAC advantages compared to other therapies.

Main Results:

  • Focus on eight PROTAC candidates in clinical development for hematologic malignancies.
  • Categorization of 56 preclinical targets into seven functional groups (e.g., epigenetic regulators, kinases).
  • Identification of PROTACs' distinct benefits in treating blood cancers.

Conclusions:

  • PROTACs represent a promising therapeutic modality for hematologic malignancies.
  • The field is expanding with numerous targets in preclinical development.
  • Further research and development are crucial for advancing PROTAC therapeutics.
Keywords:
Hematologic malignanciesProteolysis-Targeting Chimera (PROTAC)Target protein degradation (TPD)

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K